The National Institute of Health and Clinical Excellence has published new guidance for the month of January 2011. This month there is one clinical guideline and one technology appraisal that impact upon primary care.
The anxiety clinical guideline is a partial update (PDF). It provides evidence-based advice on the care and treatment of adults with generalised anxiety disorder or panic disorder with or without agoraphobia.
The technology appraisal reviews (PDF) the role of aripiprazole for schizophrenia in people aged 15 to 17 years. Aripiprazole is recommended when risperidone is contraindicated, poorly tolerated or provides inadequate control of symptoms.
Action: Clinicians should be aware of these recommendations and implement any necessary changes to practice.
|« Dronedarone linked to liver injury||1,000 post milestone »|